TGR BIOSCIENCES ANNOUNCES US PATENT GRANTED FOR ‘GOLD STANDARD’ IMMUNOASSAY TECHNOLOGY

TGR BioSciences Pty Ltd (TGR) is pleased to announce the award of patent protection for a faster and more sensitive immunoassay. The assay has a wide range of potential applications, from clinical diagnostics to the detection of plant diseases.

TGR’s CaptSure™ technology was granted a US Patent (9,086,407) on 21 July 2015, giving TGR exclusive rights to licence the technology to researchers and manufacturers around the world.

Director of TGR, Dr Michael Crouch, said that CaptSure™ technology improves the performance of standard immunoassays by providing a shorter incubation period without compromising sensitivity or quality.

“CaptSure™ improves both the speed and accuracy of these immunoassays by reducing the number of steps required to carry out a test — this results in less interference when measuring complex samples,” he said.

As opposed to conventional multi-incubation and multi-wash immunoassays, TGR’s CaptSure™ technology format requires only a single incubation and wash step — made possible by incubating the sample with both ‘capture’ and ‘detector’ antibodies at the same time. This reduces the overall assay time significantly compared to conventional assays.

In addition, the CaptSure™ technology also greatly reduces the costs of manufacturing these tests, by simplifying test development as well as reducing the amount of core reagents required.

The award of this new patent means TGR can now broaden its partnerships with other bio-manufacturing companies and laboratories to expand the use of CaptSure™ technology.

TGR BIOSCIENCES ANNOUNCES LICENSE AGREEMENT WITH DSMZ FOR PLANT VIRUS DETECTION TECHNOLOGY

TGR BioSciences Pty Ltd (TGR) is pleased to announce a license agreement with one of the largest biological resource centers in the world, the Leibniz Institute DSMZ.

With a major focus on plant virus resistance and diagnostics, particularly in an agricultural setting, its license with TGR BioSciences will provide DSMZ with non-exclusive access to TGR’s CaptSure™ technology for use in plant virus immunoassays.

Based in Braunschweig, Germany, DSMZ is not only Europe’s most comprehensive bio-resource center, with a collection of almost 40,000 items from human and animal cell lines to plant cell lines and viruses, it is also a state-of-the-art research institute.

Under the agreement, TGR will also provide antibody conjugation services, allowing DSMZ to access TGR’s proprietary antibody tagging and immobilisation technology.

Anne Hinton, CEO of TGR BioSciences, said that the license agreement shows the breadth of interest in TGR’s CaptSure™ technology, due to its broad application across a number of research fields.

“The use of CaptSure™ technology for virus detection in the agricultural sector provides unequivocal evidence of the broad utility of this immunoassay,” Ms Hinton said. “We are very pleased to be working with DSMZ in this important application.”

In comparison to conventional assays, which usually involve three separate incubations over 4-6 hours, CaptSure™ assays require only a single incubation period and can be performed within an hour, without compromising sensitivity or quality.

CaptSure™ technology also greatly reduces the costs of manufacturing these tests, by simplifying development and the amount of core ingredients required — making it the new gold standard for immunoassay technology development around the world.

Dr Wulf Menzel, Group Leader, Plant Virus Department at DSMZ said that after extensive testing, CaptSure™ technology was by far the most efficient immunoassay for their applications.

“We have extensively tested TGR’s CaptSure™ technology for our application in detecting several plant viruses,” Dr Menzel said.

“It has allowed us to produce assays with significant acceleration in speed, enabling efficient manufacturing for the development of kits for our large client base.

“We look forward to working closely with TGR in the future as we expand our assay base with CaptSure™ technology – we are planning to offer this new technology soon to the plant virus diagnostics sector under the name B-Fast ELISA”.

CONTACT:

TGR BioSciences
General Enquiries
Thebarton, SA, Australia
E. info@tgrbio.com

Leibniz Institute DSMZ
Plant Virus Department
Braunschweig, Germany
E. plantvirus@dsmz.de

TGR BioSciences Collaborates with PerkinElmer in Launch of New AlphaLISA® SureFire® Ultra Assays

PerkinElmer’s Advanced Offering Reduces Assay Time By Up to 50 Percent and Enhances Detection Process for Life Science Researchers

WHAT:

TGR BioSciences, a leading innovator of immunoassay technologies and products, today announced a collaboration with PerkinElmer, Inc. in PerkinElmer’s launch of its AlphaLISA® SureFire® Ultra™ assays. These solutions are designed to reduce assay time by up to 50 percent and to improve the protein phosphorylation detection process. This is a critical process for helping life science professionals obtain more accurate results in biotherapeutic drug discovery research.

Continue reading

Innova Biosciences and TGR BioSciences Announce Co-Marketing Agreement for Core Technologies

Combining Innova’s Lightning-Link® conjugation kits with TGR’s CaptSure™ ELISA technology simplifies ELISA development and improves sensitivity.

Cambridge, UK and Adelaide, Australia, 16 January 2014: TGR BioSciences Pty Ltd (TGR), a life sciences company focused on the development of rapid, high sensitivity ELISA systems using their CaptSure technology, and Innova Biosciences (Innova), a specialist provider of bioconjugation systems, announced that they have entered into an agreement to promote and co-market each other’s highly complementary technologies, providing customers with a major step forward in simplifying the ELISA development process, while improving sensitivity and reducing costs.

TGR has determined that combining Innova’s Lightning-Link conjugation kits for the horseradish peroxidase (HRP) labelling of antibodies with its CaptSure technology in the development of ELISA systems maximises assay sensitivity, whilst enabling the development of a wide range of ELISA assays rapidly and cost effectively. As part of the agreement Innova customers will be introduced to the CaptSure technology, with the assurance that it will work alongside the Lightning-Link reagents. Similarly, TGR customers will receive a recommendation for Lightning-Link, with the knowledge that it will be available for licensing to them, should they choose to use it alongside CaptSure products.

TGR’s CaptSure technology simplifies ELISA assays to one-step procedures, making them much faster and easier to carry out. Both assay antibodies are added to analyte at once, and after a single wash step the HRP substrate is added to develop the signal. Importantly, costs of manufacture are greatly reduced, since only a single assay plate is required (coated with CaptSure reagent) rather than a different plate for each target, and the system also requires much less assay antibodies.

Innova’s Lightning-Link conjugation system provides the ability to label antibodies with only 30 seconds hands-on time, whilst offering 100% yields and enhanced sensitivity over traditional labelling techniques and over other conjugation systems on the market.

Continue reading

TGR BioSciences Announces License Agreement with Abcam

TGR BioSciences Pty Ltd (TGR), a leading developer of advanced cell based assay technologies, is pleased to announce a license agreement with Abcam plc, of Cambridge, UK, a producer and distributor of high quality protein research tools. Under the agreement Abcam will develop and manufacture immunoassay products that incorporate TGR’s proprietary CaptSure™ assay technology. Immunoassays incorporating CaptSure are highly sensitive, offer considerable time savings, and are easy to perform when compared with conventional sandwich immunoassays.

James Murray, General Manager of Abcam Eugene commented: “We are pleased to have signed the license agreement with TGR. This innovative technology will enable Abcam to continue to develop its high quality immunoassay range by providing even greater choice to customers.”

“We’re extremely pleased that Abcam, a company at the forefront of product supply and support, has recognised the significant advantages afforded by our CaptSure immunoassay technology,” says Anne Hinton, CEO at TGR BioSciences. “Abcam is recognized around the world for providing the highest quality products and services to the Life Science community, and we are very excited to see Abcam incorporating our technology in their immunoassay products.”

TGR Scientist wins the bioinnovation SA young achiever award

TGR is delighted to announce that Dr Antony Sheehan, Principal Scientist at TGR, has been awarded the prestigious 2012 BioSA Young Achiever award. The award was presented to Dr Antony Sheehan by the Minister for Science and Information Economy, the Hon Grace Portolesi, MP, at the AusBiotech Business Development Workshop and Forum Welcome Reception on March 2019.

The award recognises Dr Sheehan’s contribution to TGR’s scientific development, commercial strategy, and his leadership skills.

Dr Sheehan joined TGR BioSciences in 2007, initially appointed as a senior scientist. Since joining TGR, Dr Sheehan has played a key role in the development of TGR’s CaptSure™ sandwich immunoassay platform which is attracting major international attention, and currently leads the R&D and product development teams.

Dr Sheehan plays a key role in aligning TGR’s technical workplans with its commercial goals and is committed to driving innovation in the research sector, particularly in the field of protein detection technologies.

For more information, contact;

Anne Hinton, CEO

ahinton@tgrbio.com, +61 8 8354 6174

TGR announce completion of ownership restructure

TGR BioSciences wishes to announce the transaction to facilitate the exit of the Nanyang Innovation Fund and Statewide Superannuation has been completed. The early investment by these shareholders was essential in assisting the Company to develop its current technologies.  The Company is pleased that Management and other current shareholders were able to fund the exit transaction confirming their commitment to the Company’s business strategy.

TGR would like to recognise the substantial contribution and support given by all of its exiting shareholders. Further, the significant commitment by departing Directors John Bastian (Independent) and Simon Uzcilas (Nanyang) greatly assisted in completion of the transaction.

TGR BioSciences is a private company located in Adelaide, Australia. Established in 2001, TGR is committed to providing innovative solutions for cell-based research applications. Our scientists have expertise in cell biology, biochemistry and immunoassay design, and have developed products and services of the highest quality, which have been used successfully in drug discovery programs around the world.

For more information, contact;

Anne Hinton, CEO, TGR BioSciences

ahinton@tgrbio.com, +61 8 8354 6174

or

Andrew Sneddon, Chairman, TGR BioSciences

asneddon@tgrbio.com

TGR Management restructure

The TGR Board wish to advise that they have appointed Ms Anne Hinton as CEO of the company effective 1 February 2012. Anne, previously TGR’s CFO/COO, brings significant commercial experience having been with the company for 10 years, and prior to that held management consulting roles in her own business and for KPMG.

Ms Hinton will succeed Dr Leanna Read, who has resigned from the company from January 31, 2012 after leading the company for over 10 years. Leanna, the founding CEO of TGR, considers that it is timely to hand over the reins and move on to new challenges.

The Board would like to thank Leanna for her considerable efforts in leading the company to a position where it is held in high regard in the international biotechnology industry.